1-year treatment with recombinant somatropin in prepubertal and pubertal growth hormone deficient patients: results from a French multicentre trial.
In this French study with recombinant somatropin, the stimulation of growth in 32 prepubertal (age 10.0 +/- 3.5 years; mean +/- SD) and 19 pubertal (age 14 +/- 1.5 years) GH deficient children was compared; the stimulation of growth was similarly good in the two groups. The height velocity SD scores increased from -2.5 +/- 1.7 and -0.9 +/- 1.5 to 2.2 +/- 1.9 and 1.6 +/- 1.6 in prepubertal and pubertal children, respectively. Expressed as cm/year, these correspond to increases from 3.2 +/- 1.3 cm/year and 4.1 +/- 1.2 cm/year to 8.1 +/- 1.5 cm/year and 8.6 +/- 1.9 cm/year in the prepubertal and pubertal patients, respectively. Safety and tolerance were good and the immunogenicity of Genotonorm was low.
Job
J C
JC
French Multicentre Trial Group, Paris, France.
Rochiccioli
P
P
Rappaport
R
R
Raux-Demay
M C
MC
Ponte
C
C
Juif
J
J
Colle
M
M
Lecornu
M
M
Leheup
B
B
Garandeau
P
P
D000293:Adolescent; D000917:Antibody Formation; D001827:Body Height / Q000187:drug effects; D002648:Child; D005260:Female; D005602:France; D013006:Growth Hormone / Q000172:deficiency* / Q000276:immunology; D006801:Humans; D008297:Male; D015337:Multicenter Studies as Topic; D011994:Recombinant Proteins
D011994:Recombinant Proteins; D013006:Growth Hormone